ES102 not checked
Inhibrx Biosciences · Elpiscience Biopharma · INBRX-106 · Hexavalent OX40 agonist antibody
FollowEvery change as it happens, and a Monday email
Trials
3 active
5 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “INBRX-106 0.1 mg/kg by intravenous (IV) infusion, given every 3 weeks (QW3)”In the company’s words, NCT06295731 on ClinicalTrials.gov
- Tested for
- Non-Small Cell Lung Cancer (2 trials), Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC), Solid Tumor, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma and 2 more
- Main trialPhase 2/3
- “This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody ordastobart (INBRX-106) combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for patients with recurrent or metastatic (R/M) HPV-positive Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) expressing PD-L1.”In the company’s words, NCT06295731 on ClinicalTrials.gov
- Other names
- INBRX-106 · Hexavalent OX40 agonist antibody · Ordastobart
Other drugs for Non-Small Cell Lung Cancer
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- CobimetinibRoche · Phase 2/3
- DivarasibRoche · Phase 3
- EntrectinibRoche · Phase 3
Coming up3
- 28 Feb 2027Phase 2 trial completes · ClinicalTrials.gov
- Dec 2029Phase 2/3 trial completes · ClinicalTrials.gov
- Jul 2033Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | Dec 2029 | Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN) | |
| Phase 2Active, not recruiting | 28 Feb 2027 | A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer | |
| Phase 1/2Recruiting | Jul 2033 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | |
| Phase 1Completed | 1 Mar 2024 | A Study of ES102 (OX40 Agonist) in Patients With Advanced Solid Tumors | |
| Phase 1Completed | 17 May 2024 | A Study of ES102 (OX40 Agonist) in Combination With JS001 in Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026